Advertisement
UK markets close in 8 hours 22 minutes

  • FTSE 100

    8,040.38
    0.00 (0.00%)
     

  • FTSE 250

    19,719.37
    0.00 (0.00%)
     

  • AIM

    754.69
    0.00 (0.00%)
     

  • GBP/EUR

    1.1657
    +0.0012 (+0.11%)
     

  • GBP/USD

    1.2493
    +0.0031 (+0.25%)
     

  • Bitcoin GBP

    51,438.82
    -1,988.03 (-3.72%)
     

  • CMC Crypto 200

    1,389.76
    +7.19 (+0.52%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.07
    +0.26 (+0.31%)
     

  • GOLD FUTURES

    2,334.60
    -3.80 (-0.16%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,277.44
    +76.17 (+0.44%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • CAC 40

    8,091.86
    -13.92 (-0.17%)
     
Property:

How to sell your home

Top tips from property investors

Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

Merus N.V.
·1-min read

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).

The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am GMT/3:00 am ET on the Investors page of the Company's website and remain available for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

CONTACT: Investor and Media Inquiries: Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl